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Abstract
During the twenty-ﬁrst century, the development of national immunization programmes (NIP) has matured into robust processes where
evidence-based methodologies and frameworks have increasingly been adopted. A key role in the decision-making and recommending
processes is played by National Immunization Technical Advisory Groups (NITAGs). In a survey performed among European Union
member states, Norway and Iceland, in February 2013, 85% of the 27 responding countries reported having established a NITAG, and of
these, 45% have formal frameworks in place for the systematic development of vaccination recommendations. Independent of whether a
formal framework is in place, common key factors are addressed by all NITAGs and also in countries without NITAGs. The four main
factors addressed by all were: disease burden in the country, severity of the disease, vaccine effectiveness or efﬁcacy, and vaccine safety at
population level. Mathematical modelling and cost-effectiveness analyses are still not common tools. Differences in the relative weighting of
these key factors, differences in data or assumptions on country-speciﬁc key factors, and differences in existing vaccination systems and
ﬁnancing, are likely to be reasons for differences in NITAG recommendations, and eventually NIPs, across Europe. Even if harmonization of
NIPs is presently not a reasonable aim, systematic reviews and the development of mathematical/economic models could be performed at
supranational level, thus sharing resources and easing the present work-load of NITAGs. Nevertheless, it has been argued that
harmonization would ease central purchase of vaccines, thus reducing the price and increasing access to new vaccines.
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Introduction
In Europe, licensure of vaccines and indications for their clinical
use are regulated by the European Medicines Agency and
national regulatory authorities. Before licensure, a candidate
vaccine undergoes extensive immunogenicity and safety
evaluations, and usually also evaluation of efﬁcacy under ideal
conditions in the intended main indication target group(s).
Once a vaccine is licensed and available on the market,
qualiﬁed medical personnel can prescribe and administer the
vaccine to individual subjects. Off-label use is discouraged, but
at times indications or schedules may be altered from those on
the label, based on an individual beneﬁt–risk assessment or on
population risk–beneﬁt or cost-effectiveness assessments.
How widely the commercially available vaccines are even-
tually used in a population depends largely on the delivery and
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ﬁnancing system of the national immunization programme
(NIP). The adoption of a vaccine in a NIP is usually linked to its
funding through public sources. In contrast to the treatment of
sick patients, vaccines as a preventive measure do not only
confer a beneﬁt on the vaccinated individual, but often also on
the total population in which the vaccine has been introduced.
The public health beneﬁts of large-scale vaccination in a
population can include overall disease burden reduction; for
several diseases, the protection of vulnerable (potentially
unvaccinated) individuals by reducing disease transmission
(herd protection); the complete elimination of a disease in a
geographic region; and/or cost-savings in the healthcare
system. To make the most efﬁcient use of a vaccine and to
maximize its beneﬁts, speciﬁc strategies can be implemented
within a NIP, e.g. by targeting either the total population or
only speciﬁc age cohorts or other population subgroups with
an increased risk of acquiring the disease or of developing
more severe disease once infected.
Since the birth of the Expanded Programme on Immuniza-
tion after successful eradication of smallpox in the 1970s, there
has been a steady drift away from thinking that one
programme can ﬁt all countries. Therefore, the WHO has
recommended and the Global Vaccine Action Plan has recently
endorsed as a strategic goal, that countries should establish or
strengthen formal and, if possible, independent technical
expert committees to guide country immunization policies
and aid national decision-making for NIPs [1,2]. The underlying
thinking is that national decision-making and recommendation
on the use of vaccines at population level should be based as
much as possible not only on universally applicable best-avail-
able scientiﬁc evidence, but also on local disease burden, and
country-speciﬁc cost-effectiveness [2]. Taking these into
account would then be the core tasks of a National Immu-
nization Technical Advisory Group (NITAG), together with
ensuring that the process of adopting a vaccine in a NIP is less
likely to depend on commercial or other vested interests.
Frameworks and Key Factors Considered by
NITAGs
A NITAG is a technical resource providing evidence-based
guidance to national authorities and policy-makers [1]. Such a
resource is particularly important in view of the complex and
vast bodies of evidence, as well as a dynamic vaccine market,
with new products targeting a variety of age groups and
speciﬁc at-risk populations [1].
To systematically assess and weigh the available evidence, to
minimize bias, to improve transparency, and to enable a
structured evaluation, different evidence-grading systems have
been developed and applied, especially for clinical practices [3].
However, the public health domain has been slow in adopting
such approaches [4]. Nevertheless, in recent years, the
approach of the Grading of Recommendations’ Assessment,
Development and Evaluation (GRADE) Working Group has
increasingly been proposed and used as a tool for the
development of evidence-based recommendations, also in
the ﬁeld of immunization [5,6]. The GRADE system has the
advantage that it does not only grade the quality of evidence
related to the efﬁcacy and safety of an intervention; it also
takes into account that other factors beyond the quality of
evidence (e.g. preferences, values and resource implications)
inﬂuence our conﬁdence that adherence to a recommendation
causes more beneﬁt than harm [7]. Another advantage of
GRADE is that the quality of evidence derived from observa-
tional studies, which in most evidence-grading systems are
considered a priori to provide lower quality of evidence, can be
up-rated under speciﬁc conditions. This is of particular
importance in the ﬁeld of immunization, because some aspects
(e.g. very rare adverse events or population-level effects such
as herd protection) are difﬁcult to assess in randomized
controlled vaccine trials [8].
Even without a methodologically rigorous system like
GRADE, most NITAGs have a framework in place to consider
various key factors when developing a recommendation [9].
These key factors are evaluated either informally or formally.
Often, decision-making tools are used, such as health tech-
nology assessment, in combination with epidemiological,
ethical and behavioural analyses; such analyses can include
mathematical modelling to predict population level and
long-term impacts in a given population, depending on different
vaccination strategies, and health-economic evaluations of
strategies. In the Netherlands, for example, the factors that
determine a vaccine’s suitability for inclusion in the NIP have
been translated into seven selection criteria, grouped under
ﬁve thematic headings: seriousness and extent of the disease
burden, effectiveness and safety of the vaccination, acceptabil-
ity of the vaccination, efﬁciency of the vaccination, and priority
of the vaccination [10]. In Canada, the analytical framework
proposed included 58 criteria classiﬁed into 13 categories [11].
As in other systems, the National Advisory Committee on
Immunization in Canada has three broad stages in the
preparation of a recommendation statement: (i) knowledge
synthesis (based on individual studies); (ii) synthesis of the
body of evidence on beneﬁts and harms, considering the
quality of the evidence and the magnitude of effects observed;
and (iii) translation of evidence into a recommendation [12].
Other frameworks have been established elsewhere; we
describe these brieﬂy for Finland, Germany and Italy in the
Supplementary material, Appendix S1 [13,14].
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A global survey of NITAGs was conducted by the WHO in
2008. Of the 193 eligible countries, 147 participated, including
47 of the 53 European countries [9]. In Europe, 34 (72%)
responding countries stated that they had a NITAG. In the 88
countries with NITAGs, key factors that are considered when
a NITAG makes recommendations were: vaccine safety
(100%), disease burden in the home country (99%), disease
epidemiology (95%), ﬁnancial aspects (91%) and public per-
ception of the disease (59%) [9].
Information on NITAG composition, ways of working, and
decisions made, as well as indicators to assess NITAGs [15],
can be found online from several national sites as well as via
web portals. The WHO holds a resource website of NITAGs
(www.who.int/immunization/sage/national_advisory_ commit
tees/en/). Also, the SIVAC (Supporting National Independent
Immunization and Vaccine Advisory Committees; www.sivac.
org/about-sivac) initiative established in 2008, holds a NITAG
observatory, where links to 43 NITAGs around the world,
including 11 European countries, can be found (www.
nitag-resource.org/en/observatory/dashboard.php).
2013 Survey on NITAGs in the European
Union, Iceland and Norway
Expressly for this review, we conducted, in February 2013, a
web-based survey (www.surveymonkey.com) on NITAG
qualities and processes among the gatekeepers of the project
‘Vaccine European New Integrated Collaboration Effort’
(VENICE; http://venice.cineca.org). Country contact points
working with national vaccination programmes in 27 European
Union (EU) Member States, Norway and Iceland, were
approached and requested to ﬁll in the questionnaire.
If the gatekeepers were not the key holders of the requested
information, they were asked to identify a competent expert
instead, who would then ﬁll in the questionnaire. Furthermore,
in addition to ﬁlling in the structured survey forms, a brief
description of the process of inclusion of a vaccine in theNIP and
the main factors considered for the decision were requested
from all, including countries without a NITAG.
By April 2013, 27 (93%) countries had completed the
survey. Only Hungary and Portugal did not respond.
Twenty-three (85%) countries reported having a NITAG
(Table 1). Cyprus, Italy, Norway and Sweden reported that
they did not have a NITAG. Sweden mentioned, however, that
the Swedish National Board of Health has, as a national
authority, responsibilities similar to a NITAG. Most NITAGs
had been active for many years: the oldest, since 1902. Five
NITAGs were established in 2006 or later. The number of
NITAG-members ranged from seven to 35 (median 14). In 17 T
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of 22 NITAGs, members are requested to declare their
potential conﬂicts of interest. In Table 2, the professional
expertise of NITAG members is described. Clinicians, epi-
demiologists and paediatricians are the most frequently
represented professional groups in NITAGs.
Besides regular members, permanent guests without voting
rights can attend NITAG meetings in 17 countries. In 23
countries, external experts are temporarily invited for speciﬁc
topics. In eight NITAGs, representatives of the pharmaceutical
industry are occasionally invited as external experts. In one
country, theNITAGmeetings are public, unless a decision to the
contrary has been made; in another country, NITAG meetings
are sometimes public. Minutes are published online by seven
NITAGs, while another six provide minutes upon request.
Ten of the 22 countries with NITAGs stated that their
NITAG had a framework for the formal process when
recommending a vaccine for the NIP. Currently, two countries
apply the GRADE methodology (Germany and France). In four
out of 23 countries, the NITAG can give different degrees of
strength to its recommendation. Table 3 summarizes the key
factors of NITAG decision-making: disease burden in the
country, severity of the disease, vaccine effectiveness or efﬁcacy,
and vaccine safety at population level were the four common
factors shared by the NITAGs of all responding countries.
In all 23 countries that have a NITAG and that provided a
response to this question, a separate governmental or health
insurance structure entity makes the ﬁnal decision on NIP
inclusion or reimbursement of vaccination. In 16 of these 23
countries, NITAGs provide information directly to the
national entity that takes this ﬁnal decision. In the remaining
seven NITAGs, the decision needs to be validated by another
entity before ﬁnal decision-making (e.g. a National Board or
Intra-territorial Council or a National Public Health Institute,
or Public Health Authorities).
Reasons for Differences in NITAG
Recommendations and NIP Schedules
Despite similar key criteria considered by NITAGs in Europe,
substantial differences in vaccination schedules (http://vac-
cine-schedule.ecdc.europa.eu/Pages/Scheduler.aspx) and poli-
cies exist [16,17]. Besides historical reasons, these differences
can partially be explained by differences in the vaccination
TABLE 2. Professional expertise represented among
National Immunization Technical Advisory Group (NITAG)
members in 22 countries with NITAGs (a).
Field Countries Proportion (%)
Clinical medicine 22 100
Epidemiology 21 96
Paediatrics 20 91
Public health 18 82
Microbiology (incl. Virology) 17 77
Immunology 16 73
Vaccinology 16 73
Health economics 5 23
General practice 5 23
Regulatory Authority on Medicines 5 23
Ministry of Health 2 9
Social sciences 2 9
‘Well-baby clinics’ 2 9
University faculty 1 5
Ethics 1 5
Health insurance system 1 5
Lay members 1 5
Occupational health 1 5
Non-governmental organizations 1 5
School Health Medicine 1 5
Travel medicine 1 5
aSpain is not included because the composition of NITAGs varies by Region.
TABLE 3. Key factors considered in the decision-making process of adopting vaccines in the national immunization programme
of surveyed countries (n = 21 with and n = 5 without a National Immunization Technical Advisory Group (NITAG)
Factor
Number of
countries that
consider this a
key factor (n)
Number of
responding countries (n) Proportion (%)
Disease burden in home country 25 25 100
Severity of disease 25 25 100
Vaccine efﬁcacy/effectiveness 25 25 100
Vaccine safety at population level 25 25 100
Vaccine safety at individual level 23 25 92
Feasibility of recommendation 23 25 92
Guidance document from WHO 22 25 88
Priority among other vaccine-preventable diseases 21 25 84
Results from economic evaluations 20 25 80
Guidance document from ECDC 20 25 80
Recommendations of other countries 18 24 75
Method of vaccine administration 14 24 58
Priority of vaccination compared with all other
possible health interventions
12 24 50
Results from mathematical modelling 11 24 46
Public perception about the disease 10 24 44
Disease burden in neighbouring country 7 24 29
Feasibility of local vaccine production 1 24 4
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systems, including funding schemes and the role of responsible
authorities in decision-making regarding inclusion of a vaccine
in a NIP. The UK, the Netherlands and Finland are examples of
centralized systems with government-funded vaccination pro-
grammes and central vaccine procurement (see country
examples in the Supplementary material, Appendix S1). In
contrast, Germany is an example of a decentralized, private
vaccination system, where vaccinations are reimbursed by
statutory health insurances, and vaccines are usually adminis-
tered by a private physician who can freely choose among
vaccine brands available on the market. Italy, on the other
hand, has a decentralized public health system with govern-
ment-funded vaccination programmes and 21 regions free to
decide on schedules, brand of vaccines and the organization of
regional immunization activity. This explains why some key
factors play a more dominant role in some NITAGs than in
others, for example: health-economic evaluations in countries
with a centralized system.
Most NIP vaccines are given in the ﬁrst 2 years of life,
because they protect against highly contagious diseases that
affect mainly young children and children in this age-group are
most vulnerable. All European countries have recommenda-
tions and give vaccines against tetanus, diphtheria, pertussis,
polio, Haemophilus inﬂuenzae type b (Hib), measles, mumps and
rubella in their NIP [16]. Even if these vaccines are common,
the antigen composition, schedules, co-administration and
dosing often differ by country. Partly, this could be a result of
different interpretations of the immunological impacts of the
varying schedules or of the lack of evidence documenting that
one schedule works better than the others in reducing disease
incidence in the population.
Issues of Vaccination Systems, Financing
Schemes and Pooling Contracts
For the other childhood vaccines, there are even more
differences among countries. In addition to the above-men-
tioned reasons, ﬁnancial and organizational considerations also
play an important role. In some countries, systems are in place to
decrease the vaccine dose price to levels comparable to the
estimated country-speciﬁc threshold price, either through a
formal tender system or through negotiations by responsible
authorities on the vaccine dose price when integrated into an
NIP. Organizational aspects are important, especially when
integrating a new vaccine into the existing health systems. The
healthcare costs of both the existing NIP and ‘well-baby’
programmes need to be re-considered, for example by
synchronizing the vaccination visits with other growth and
development monitoring activities in the well-baby clinics and
vaccination centres, which increases the acceptance and atten-
dance rate of parents.
Even within a single country, there may exist differences in
baseline disease burden and risk among different population
subgroups, depending, for example, on age, gender, underlying
chronic disease, access to health care or other socio-demo-
graphic parameters. Therefore, the baseline disease burden
and risk in different population subgroups must be considered
when weighting the beneﬁts and costs of different vaccination
strategies. Again, these factors may vary from country to
country, and therefore it is a major task of each NITAG to
review such data at country-level and suggest the most
efﬁcient vaccination strategy accordingly. In addition to
group-speciﬁc baseline disease risk, other infectious or societal
factors might inﬂuence a NITAG’s decision to target speciﬁc
population-subgroups.
Yet more country-speciﬁc key factors considered by
NITAGs may contribute to differences in vaccination sched-
ules and policies across Europe. These include, for example:
 data on local disease incidence, which may or may not be
readily available;
 disease-related and vaccination-related costs, which depend
on the healthcare system in place. Both impact health
economic evaluations, which in turn are dramatically inﬂu-
enced by tendering and negotiation practices for vaccine
prices in the country;
 the degree towhich a health-economic evaluation is taken into
consideration and assumptions made for it (such as indirect
costs and discounting); this degree may differ in the deci-
sion-making process of a NITAG or other deciding bodies;
 preferences and values (which might be inﬂuenced by
cultural differences) may or may not play a role; and
 availability of speciﬁc vaccines may differ, though local
production is nearly non-existent nowadays.
Below, we present ﬁve examples on how and why NIPs
differ, and we try to elucidate the role of NITAGs in the
relevant decisions.
Example 1. Hepatitis B Vaccine for Children
Hepatitis B virus (HBV) vaccines are given universally to
children in all European countries except the UK, Denmark,
Norway, Sweden, Iceland and Finland (16). Some of these
countries state that their HBV disease burden is too low to
economically justify universal vaccination, and therefore they
have instead chosen to target special risk groups. However, a
universal programme might become cost-effective with com-
bination vaccines, if the vaccine price is low enough.
ª2013 The Authors
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Example 2. Rotavirus Vaccine for Children
As of today, rotavirus vaccine is given universally to infants as
part of the NIP only in Austria, Finland and Luxembourg. In
Belgium, universal rotavirus vaccination is recommended by
the NITAG but is not included in the NIP. However, though
the vaccine is only partially reimbursed, a high coverage is
reached thanks to the participation of well-baby clinics [18]. In
the UK, a decision to include rotavirus vaccine in the NIP has
recently been made [19]. In some of these countries, formal
cost-effectiveness evaluation has demonstrated that rotavirus
vaccination can be justiﬁed on reasonable economic grounds
[20]. In other countries, the assumed price of the vaccine has
mostly been unfavourable in relation to the perceived burden
of rotavirus disease to the society.
Example 3. Vaccination of Girls Against
Human Papillomavirus
Vaccination programmes against human papillomavirus (HPV)
mostly target adolescent girls only [21]. Most countries
analysed the cost-effectiveness of various options. Factors
considered—in addition to price—for the recommendation
are HPV-associated disease burden in the country: most
importantly, cervical cancer and the ability of the cancer
screening test (Papanicolaou) and HPV-screening systems in
place to detect it early. Depending on the main aim of the
programme, genital warts and other HPV-associated cancers
might also weigh in the decision. As HPV is sexually
transmitted and often acquired soon after sexual debut, the
vaccine needs to be given before exposure to HPV. Hence, the
average age of sexual debut, and probable acceptance of a
vaccination against a sexually transmitted disease by the target
group and their guardians all play a role [22].
As of November 2012, HPV vaccines have been adopted in
the NIP of 21 of 29 surveyed European countries (27 EU
Member States plus Iceland and Norway) [21] (Fig. 1).
Whereas in most countries the adopted vaccination policy
targets only females, both females and males are recom-
mended to be vaccinated in Austria [21]. Adolescents aged
12 years were chosen as the target population for routine
vaccination in eight countries, while girls aged 11, 13, 14 years,
or an age range including several birth cohorts, were chosen in
the other Member States [21].
Example 4. General Adult Vaccination
Schedules
Depending on the country, adult vaccine recommendations
range from the almost non-existent to the over-abundant. In
the 29 EU and European Economic Area (EEA) member states,
between four and 16 vaccines are recommended to adults
[23]. All countries have recommendations for adults univer-
sally or adult subgroups to be vaccinated against seasonal
inﬂuenza and hepatitis B, followed by recommendations for
prophylactic tetanus and diphtheria vaccination, which exist in
76% and 72% countries, respectively [23]. In recent years, with
the upsurge of pertussis, acellular pertussis vaccine has also
been increasingly viewed as an adult vaccination, and different
strategies have been implemented across Europe to combat
the re-emergence of pertussis [24]. For example, in the UK,
acellular pertussis vaccine has been recommended to all
pregnant women since autumn 2012 to avert infant pertussis,
while in Germany, a cocoon strategy is in place that targets all
household contacts of newborns and so provides an additional
FIG. 1. Countries with human papillomavirus (HPV) vaccine introduced into the national immunization programme (NIP; as of November 2012), in
the European Union, Iceland and Norway.
ª2013 The Authors
Clinical Microbiology and Infection ª2013 European Society of Clinical Microbiology and Infectious Diseases, CMI, 19, 1096–1105
CMI Nohynek et al. NITAG, evidence and vaccination policy making 1101
booster dose to the German adults who otherwise would
receive only one booster dose in their life time [25,26].
Example 5. Vaccination Against Seasonal
Inﬂuenza
For seasonal inﬂuenza vaccination, most European countries
target population subgroups with an increased risk of devel-
oping severe disease, especially individuals with chronic
underlying conditions and/or persons above 55 or 60 or
65 years [23,27]. Healthcare workers are also considered as a
key target group for inﬂuenza vaccination, mainly to reduce
work absenteeism and because of their crucial position in
caring for those who need the most protection from inﬂuenza,
but also because they could set a positive example to others.
Another special group recently added to the target list is
pregnant women. Despite evidence for increased risk of
complications of inﬂuenza in advancing pregnancy [28] and the
lack of adverse events to the offspring when the mother has
been vaccinated [29], several European countries are hesitant
to follow the advice of the Strategic Advisory Group of WHO
to make this recommendation, indicating that evidence is being
weighted differently [30,31].
Differences also exist in paediatric or adolescent inﬂuenza
vaccination policy. As of 2009, only six of 27 (22%) EU/EEA
member states recommended inﬂuenza vaccination of healthy
children aged between 6 months and <18 years [27]. This may
suggest knowledge gaps (e.g. evidence related to the occur-
rence of herd protection), lack of data on the local disease
burden, conﬂicting reports on inﬂuenza vaccine efﬁcacy and/or
effectiveness in young children, and ﬁnally, value differences
among NITAGs [27]. Value differences may be the result of
various factors, including the ethical dilemma when routinely
vaccinating healthy children with non-perfect vaccines, with
one of the main goals being to reduce overall disease
transmission and thereby (indirectly) also reduce disease
incidence in the elderly and more vulnerable population.
NITAG Recommendations and Inclusion of
Vaccines in the NIP
Despite obvious disease burden and available intervention
options, not all vaccines are included in every country’s NIP.
The primary role of NITAGs is to develop recommendations
to guide national authorities and policy makers. As demon-
strated in our survey, in all European countries with NITAGs,
there are separate governmental or health insurance author-
ities that make the ﬁnal decision of whether to adopt a new
vaccine in the NIP, or whether to reimburse the vaccine (Fig.
2). For this reason, in some instances, a NITAG can endorse a
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FIG. 2. A schematic description of the decision-making process for recommending the inclusion of a new vaccine in the national immunization
programme in Finland. The National Immunization Technical Advisory Group (NITAG) covers the process from decision on the formation of a
vaccine-speciﬁc expert group to providing a recommendation to the National Institute for Health and Welfare. NIP, national immunization
programme; CEA, cost effectiveness analysis; MSAH, ministry of social affairs and health.
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recommendation for a vaccine, but the vaccine is not adopted
into the NIP, e.g. for economic reasons. In some countries
with more regional autonomy, additional committees or
authorities are responsible for decision-making at subnational
level. This explains why there are sometimes even different
recommendations or programmes within a country.
In many countries, vaccines included in a NIP are free of
charge or reimbursed by health insurance. On the contrary,
vaccines not included in the NIP but available on the market
and administered according to the indications in the licensure
are either paid out-of-pocket or only partially reimbursed.
This emphasizes the additional role and importance of a
NITAG as an advisory body serving clinicians in their decision
process for individual patients or patient groups. The situation
is complicated when the available scientiﬁc evidence is
non-existent, weak or contradictory. A recent example is
provided by the recommendation of pneumococcal vaccines
for adults to prevent invasive and non-invasive pneumococcal
diseases. The superiority of the conjugate over the polysac-
charide pneumococcal vaccine in prevention of invasive
disease is still a subject of academic dispute [32,33]. Labora-
tory results pointing to the polysaccharide vaccine causing
hypo-responsiveness in those vaccinated is challenged by
clinical observations [34]. Key clinical opinion leaders may be
inﬂuenced by the pharmaceutical industry, at the same time
that evidence on the impact of the conjugate vaccine on the
main outcome from public health perspective, i.e. adult
pneumonia, is still lacking.
In these instances, NITAGs—in their role of advising
national authorities—may decide to await additional evidence
from not yet published studies or from the experience of
other countries that have already introduced the programme.
The GRADE working group suggests that in circumstances in
which panels, such as NITAGs, choose not to make a
recommendation, they should specify whether this is on the
basis of very low conﬁdence in the effect estimates, or because
they think the balance between desirable and undesirable
consequences is so close that they cannot make a recommen-
dation [7]. In many countries, NITAG recommendations also
serve as “best practice guidelines” for physicians, so lacking a
recommendation should not obviate physicians from taking a
decision whether to vaccinate or not on an individual patient
basis. Recommendations from other entities, e.g. professional
societies, might be available and support the physician in taking
this decision. In the case of pneumococcal vaccines, human
immunodeﬁciency virus experts and lung specialists may want
to formulate their own recommendations just as clinicians
treating patients with rheumatoid arthritis have formulated
recommendations regarding the use of vaccines for patients
receiving immuno-modulatory treatments [35].
Future Considerations
The systematic development of evidence-based vaccination
recommendations by NITAGs requires a lot of resources,
time and effort. If transmission modelling and costing
analyses are included, the evaluation easily takes several
years to complete. In addition, not all countries have the
resources and expertise available to conduct these analyses
as a standard procedure when developing vaccination
recommendations. Presently, for the majority of European
countries, the most resource-consuming, but also most
important, part of the decision-making process is the
systematic review of the literature and assessment of the
quality of available evidence. Often, the same review work is
conducted by each NITAG individually. This task offers itself
to putative synergies and interaction among countries, which
could be facilitated by supranational bodies, such as the
European Centre for Disease Prevention and Control or the
WHO. Here, the aim should be on reducing the duplication
of effort by focusing on common key factors used by
NITAGs that are not country-speciﬁc, namely the
assessment of the quality of evidence related to vaccine
effects and vaccination programme effects at population level
[36].
While the Paediatric Committee of the European Med-
icines Agency, vaccine manufacturers, and several authors
have called for the harmonization of immunization schedules,
arguing that a single, uniform immunization schedule would
be ethical, cost-saving, would facilitate mobility of EU
residents, improve data collection, and increase vaccination
coverage, other authors doubt that these arguments are
either quantitatively or qualitatively appropriate [37].
Harmonization might be even ethically problematic, given
that, as described above, many factors considered by
NITAGs, such as disease burden or cost-effectiveness, are
often country-speciﬁc. Even though making recommenda-
tions and harmonizing vaccination schedules at the European
level could save on limited resources and facilitate the
research and development of new vaccines, harmonization is
also not foreseen as a realistic goal in the light of present
policies and the situation of decision-making in Europe. At
this stage, therefore, making transparent the path from
evaluation to recommendation to ﬁnal decision of imple-
mentation in the NIP would increase understanding and
conﬁdence within each country as well as across countries,
and ultimately contribute to epidemiologically, immunologi-
cally and economically better justiﬁed vaccination pro-
grammes.
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Appendix 1
VENICE National Gatekeepers: Berthet, Francoise (Luxem-
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De Melker, Hester (Netherlands), Feiring, Berit (Norway),
Floret, Daniel (France), Gill, Denis (Ireland), Gudnason,
Thorolfur (Iceland), Hudecova, Helena (Slovakia), Iannazzo,
Stefania, (Italy), Kerbo, Natalia (Estonia), Kojouharova, Mira
(Bulgaria), Kraigher, Alenka (Slovenia), Kriz, Bohumir (Czech
Republic), Limia, Aurora (Spain), Lileikyte, Ausra (Lithuania),
Melillo, Tanya (Malta), Nohynek, Hanna (Finland), O’Flanagan,
Darina (Ireland), Paradowska-Stankiewicz, Iwona (Poland),
Pebody, Richard (United Kingdom), Perevoscikovs, Jurijs
(Latvia), Sabbe, Martine (Belgium), Soteriou, Soteroulla
(Cyprus), Stavrou, Theodora (Greece), Top, Geert (Belgium),
Tegnell, Anders (Sweden), Valentiner-Branth, Palle (Denmark),
Van Damme, Pierre (Belgium), Wichmann, Ole (Germany),
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